The announcement of a class action lawsuit against Revance Therapeutics is likely to negatively impact its stock price in the short term as investors may react to the potential legal and financial consequences. The lawsuit suggests possible issues with the company's disclosures or operations, which could lead to financial liabilities or reputational damage.